X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Edible Sensors Give HIV Patients Actual Antiviral Dose Data

Content Team by Content Team
18th November 2022
in Clinical Trials, News

A new ingestible sensor system that was put to the test in an interventional clinical trial gave HIV patients real-time antiretroviral dosage information, helping them to better manage their infection.

The Proteus Digital Health Feedback (PDHF) information technology system kept track of 130 HIV patients’ medication regimens and informed them in real-time when a dose had been taken. The participants had lower viral loads because they were more compliant with taking antiretrovirals (ARVs), according to the data.

This research uses an ingestible sensor device for ARV therapy in HIV-infected adults for the first time. The results are a key step in measuring and tracking HIV patients’ adherence to their treatment regimens and creating in-the-moment interventions to increase patient adherence.

A tiny edible sensor used by PDHF is over-encapsulated with medicine. A patient-worn patch with an inbuilt monitor and sensor detects when anything has been consumed. A mobile device receives a Bluetooth signal from the monitor and delivers an encrypted message to a central database.

Data from the ingestible sensor’s clinical trials

Participants were chosen from HIV clinics in the US and randomly assigned to either the conventional care (UC) or information system (IS) groups.

Compliance with antiretroviral therapy was the intervention program’s main result. Plasma HIV RNA and participant satisfaction with and acceptance of the system were the secondary outcomes. The researchers found that greater plasma HIV RNA management is associated with higher levels of ARV adherence. More than 90% of people were satisfied with the system overall. The analyses comprised all 112 (IS = 54, UC = 58) participants who had finished baseline with at least one follow-up data collection.

According to Dr. Eric Daar, co-principal investigator for the study, Chief, Division of HIV Medicine at Harbor-UCLA Medical Center, and Professor of Medicine at the David Geffen School of Medicine at UCLA, when patients first registered in the study, they were having difficulty with consistent adherence to their medications.

Participants frequently stated, according to Daar’s addition, that the system gave them the extra encouragement and feedback they needed to properly manage their HIV infection.

co-principal investigator for the study and chair of the Section of Public and Population Health in the UCLA School of Dentistry, Dr. Honghu Liu, said that edible sensor technology is currently the most cutting-edge and accurate IT-based tool for measuring and tracking adherence behaviour with remote and real-time processes through a mobile device.

The research group included scientists from UCLA, Nebraska Medical Center, Yale University, and Harvard University who analysed the systems’ accuracy and evaluated their effectiveness for tracking and leveraging drug adherence. The study was funded by a $4 million grant from the National Institute of Mental Health (NIMH).

Previous Post

A New Antibiotic Goal Is Established In Britain By ABPI

Next Post

WHO Emergency May Compel Big Pharma To Declare State Deals

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

WHO Emergency May Compel Big Pharma To Declare State Deals

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In